Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer
Abstrak
Patients with cancer experience a higher burden of SARS-CoV-2 infection, disease severity, complications, and mortality, than the general population. SARS-CoV-2 mRNA vaccines are highly effective in the general population; however, few data are available on their efficacy in patients with cancer. Using a prospective cohort, we assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021. Among 131 patients, most (94%) achieved seroconversion after receipt of two vaccine doses. Seroconversion rates and antibody titers in patients with hematological malignancy were significantly lower than those with solid tumors. None of the patients with history of anti-CD-20 antibody in the 6 months before vaccination developed antibody response. Antibody titers were highest for clinical surveillance or endocrine therapy groups and lowest for cytotoxic chemotherapy or monoclonal antibody groups.
Topik & Kata Kunci
Penulis (20)
A. Addeo
Pankil K. Shah
N. Bordry
R. Hudson
Brenna Albracht
Mariagrazia Di Marco
V. Kaklamani
P. Dietrich
B. Taylor
Pierre Simand
Darpan Patel
Jing Wang
I. Labidi-Galy
S. Fertani
R. Leach
Jose Sandoval
R. Mesa
K. Lathrop
N. Mach
D. Shah
Akses Cepat
- Tahun Terbit
- 2021
- Bahasa
- en
- Total Sitasi
- 215×
- Sumber Database
- Semantic Scholar
- DOI
- 10.1016/j.ccell.2021.06.009
- Akses
- Open Access ✓